Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Open accessThe DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index.
Abstract
This paper discusses the current evidence from animal and human studies for a central role of inflammation in schizophrenia. In animal models, pre- or perinatal elicitation of the immune response may increase immune reactivity throughout life, and similar findings have been described in humans. Levels of pro-inflammatory markers, such as cytokines, have been found to be increased in the blood and cerebrospinal fluid of patients with schizophrenia. Numerous epidemiological and clinical studies have provided evidence that various infectious agents are risk factors for schizophrenia and other psychoses. For example, a large-scale epidemiological study performed in Denmark clearly showed that severe infections and autoimmune disorders are such risk factors. The vulnerability-stress-inflammation model may help to explain the role of inflammation in schizophrenia because stress can increase pro-inflammatory cytokines and may even contribute to a chronic pro-inflammatory state. Schizophrenia is characterized by risk genes that promote inflammation and by environmental stress factors and alterations of the immune system. Typical alterations of dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission described in schizophrenia have also been found in low-level neuroinflammation and consequently may be key factors in the generation of schizophrenia symptoms. Further support for the relevance of a low-level neuroinflammatory process in schizophrenia is provided by the loss of central nervous system volume and microglial activation demonstrated in neuroimaging studies. Last but not least, the benefit of anti-inflammatory medications found in some studies and the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotics provide further support for the role of inflammation in this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of altered inflammation-related markers across psychiatric conditions [6–8], along with reports of anti-inflammatory effects from psychotropic medications [9, 10] and the ameliorative impact of anti-inflammatory drugs on psychiatric symptoms [11–14], suggests a strong link between abnormal inflammatory responses and major psychiatric disorders.”
From Inflammatory ratios as predictors of length of hospitalization in psychiatric patients: A multicenter study (2025) · doi:10.1007/s00406-025-02033-9 · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A growing body of evidence suggests that immune dysfunction and inflammation have been considered to play important roles in the pathogenesis of SCZ and BD (11, 12).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Changes of some inflammation-related factors (IRFs) have been intensively studied and reviewed in relation to psychiatric disorders1–9.”
From Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recent evidence suggests the involvement of the immune system in several psychiatric conditions [203–205]; one of the most studied in this respect is depression [206–208].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Vulnerability: A new view of schizophrenia.
Zubin, J., & Spring, B. (1977) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.86.2.103 · Cited by 1,992
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Maternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia
Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., Babulas, V. P., & Susser, E. S. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.774 · Cited by 1,053
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Neuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cited by
Wang, Q., Xu, R., & Volkow, N. D. (2021) · World Psychiatry · doi:10.1002/wps.20806 · Cited by 617
Yuan, N., Chen, Y., Xia, Y., Dai, J., & Liu, C. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0570-y · Cited by 428
Association of Psychiatric Disorders With Mortality Among Patients With COVID-19
Nemani, K., Li, C., Olfson, M., Blessing, E. M., Razavian, N., Chen, J., Petkova, E., & Goff, D. C. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.4442 · Cited by 375
Cytokine Alterations in Schizophrenia: An Updated Review
Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00892 · Cited by 276
Marx, W., Veronese, N., Kelly, J. T., Smith, L., Hockey, M., Collins, S., Trakman, G. L., Hoare, E., Teasdale, S. B., Wade, A., et al. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab037 · Cited by 242
Halstead, S., Siskind, D., Amft, M., Wagner, E., Yakimov, V., Shih-Jung Liu, Z., Walder, K., & Warren, N. (2023) · The Lancet Psychiatry · doi:10.1016/s2215-0366(23)00025-1 · Cited by 238
Smucny, J., Dienel, S. J., Lewis, D. A., & Carter, C. S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01089-0 · Cited by 231
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders
Huang, Y.-S., Ogbechi, J., Clanchy, F. I., Williams, R. O., & Stone, T. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00388 · Cited by 187
Critical Neurotransmitters in the Neuroimmune Network
Hodo, T. W., de Aquino, M. T. P., Shimamoto, A., & Shanker, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01869 · Cited by 184
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Tandon, R., Nasrallah, H., Akbarian, S., Carpenter, W. T., DeLisi, L. E., Gaebel, W., Green, M. F., Gur, R. E., Heckers, S., Kane, J. M., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2023.11.015 · Cited by 179
Smigielski, L., Jagannath, V., Rössler, W., Walitza, S., & Grünblatt, E. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0601-3 · Cited by 168
COVID-19 vaccination for people with severe mental illness: why, what, and how?
Mazereel, V., Van Assche, K., Detraux, J., & De Hert, M. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30564-2 · Cited by 170
Dunleavy, C., Elsworthy, R. J., Upthegrove, R., Wood, S. J., & Aldred, S. (2022) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13416 · Cited by 169
Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy
Leone, G. M., Mangano, K., Petralia, M. C., Nicoletti, F., & Fagone, P. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041630 · Cited by 160
Chen, M., Ruan, G., Chen, L., Ying, S., Li, G., Xu, F., Xiao, Z., Tian, Y., Lv, L., Ping, Y., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.817100 · Cited by 188
Schizophrenia and inflammation research: a bibliometric analysis
Sun, H.-L., Bai, W., Li, X.-H., Huang, H., Cui, X.-L., Cheung, T., Su, Z.-H., Yuan, Z., Ng, C. H., & Xiang, Y.-T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907851 · Cited by 148
“The potential reason for the expansion of research might be due to the increasing recognition of the role of inflammation (30) in the development of SCZ (31) and, therefore, increased research funding in this field.”
BackgroundBora, E. (2019) · Psychological Medicine · doi:10.1017/s0033291719001685 · Cited by 172
“Other authors have proposed a potential role for inflammation in schizophrenia (Kirckpatrick and Miller, 2013; Khandaker et al., 2015; Najjar and Pearlman, 2015; Müller, 2018).”
BackgroundNeuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway
Vallée, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052810 · Cited by 166
“This process supports the idea that the involvement of the glutamatergic pathway and NMDA receptor is major in schizophrenic patients [15,32].”
BackgroundThe Role of Inflammation in the Treatment of Schizophrenia
Fond, G. B., Lançon, C., Korchia, T., Auquier, P., & Boyer, L. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00160 · Cited by 165
Oxidative Stress and the Pathophysiology and Symptom Profile of Schizophrenia Spectrum Disorders
Murray, A., Rogers, J. C., Katshu, M. Z. U. H., Liddle, P. F., & Upthegrove, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.703452 · Cited by 168
“It should be noted that there is some contention as to whether peripheral biomarkers can reflect the status of the CNS (25).”
BackgroundInfluentialNeuroinflammation and Schizophrenia
Buckley, P. F. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1050-z · Cited by 123
Effects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
“The model implies that genetic makeup predisposes the subject to be easily affected by stress, which would show inflammatory responses later in life [5].”
Backgroundde Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccarelli, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02976-3 · Cited by 113
“In the last decade, multiple evidence from clinical, preclinical, and post-mortem studies have corroborated the inflammation and immune-related hypothesis of schizophrenia pathogenesis [3, 4, 324] fueling more robust interpretation on the role of inflammatory and immune processes in the framework of neurotransmitters…”
BackgroundGoldsmith, D. R., & Rapaport, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00046 · Cited by 122
Long term impact of Covid-19 infection on sleep and mental health: A cross-sectional study
Ahmed, G. K., Khedr, E. M., Hamad, D. A., Meshref, T. S., Hashem, M. M., & Aly, M. M. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114243 · Cited by 123
“It has been linked to the pathogenesis of depression (Beurel et al., 2020), schizophrenia (Müller, 2018), and bipolar disorder (Benedetti et al., 2020), and also the systemic manifestations of COVID-19 infection (Steardo et al., 2020).”
BackgroundParellada, E., & Gassó, P. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01385-9 · Cited by 100
Wei, Y., Wang, T., Li, G., Feng, J., Deng, L., Xu, H., Yin, L., Ma, J., Chen, D., & Chen, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.941728 · Cited by 99
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Fišar, Z. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110626 · Cited by 111
Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
Caruso, G., Grasso, M., Fidilio, A., Tascedda, F., Drago, F., & Caraci, F. (2020) · Pharmaceuticals · doi:10.3390/ph13120457 · Cited by 87
“Inflammatory reactions could be both beneficial (neuroprotective) and detrimental (neurotoxic) to the CNS, depending on the interactions occurring between environmental factors, genetic variations, and various components of the inflammatory response [59].”
BackgroundSex differences in the blood–brain barrier: Implications for mental health
Dion‐Albert, L., Binder, L. B., Daigle, B., Hong-Minh, A., Lebel, M., & Ménard, C. (2022) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2022.100989 · Cited by 107
“Changes in central and peripheral inflammatory mediators have been observed in MDD (Enache et al., 2019; Schiepers et al., 2005), BD (O’Brien et al., 2006) and SZ (Maes et al., 2002; Müller, 2018; Upthegrove and Khandaker, 2020) and have often been proposed as potential biomarkers (see Section 6).”
Backgroundde Bartolomeis, A., Vellucci, L., Barone, A., Manchia, M., Luca, V. D., Iasevoli, F., & Correll, C. U. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108236 · Cited by 98
Molecular signature of extracellular matrix pathology in schizophrenia
Pantazopoulos, H., Katsel, P., Haroutunian, V. H., Chelini, G., Klengel, T., & Berretta, S. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15009 · Cited by 84
Dienel, S. J., Schoonover, K. E., & Lewis, D. A. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.03.002 · Cited by 94
Sabé, M., Chen, C., Perez, N., Solmi, M., Mucci, A., Galderisi, S., Strauss, G. P., & Kaiser, S. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104979 · Cited by 94
“Such conflation can be seen with the cluster on „inflammation‟, which is rather nonspecific to negative symptoms, with highly cited papers mainly on the link between inflammation, genetics, depression or specific risk factors for schizophrenia (Müller, 2018; Sekar et al., 2016; Upthegrove et al., 2017).”
BackgroundMechanisms Underlying the Comorbidity of Schizophrenia and Type 2 Diabetes Mellitus
Mizuki, Y., Sakamoto, S., Okahisa, Y., Yada, Y., Hashimoto, N., Takaki, M., & Yamada, N. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa097 · Cited by 93
“Inflammation Abnormality—Inflammation is a necessary response to infection, harmful chemicals, and tissue damage (Muller, 2018).”
BackgroundGalectin-3: Roles in Neurodevelopment, Neuroinflammation, and Behavior
Srejovic, I., Selakovic, D., Jovicic, N., Jakovljević, V., Lukic, M. L., & Rosic, G. (2020) · Biomolecules · doi:10.3390/biom10050798 · Cited by 76
Barron, A., McCarthy, C., & O’Keeffe, G. W. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02290-4 · Cited by 82
de Bartolomeis, A., Barone, A., Begni, V., & Riva, M. A. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106078 · Cited by 86
Quintero, J., Gutiérrez-Casares, J. R., & Álamo, C. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00392-2 · Cited by 70
Peripheral immune markers and antipsychotic non-response in psychosis
Enache, D., Nikkheslat, N., Fathalla, D., Morgan, B. P., Lewis, S. W., Drake, R., Deakin, J. F. W., Walters, J., Lawrie, S. M., Egerton, A., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.020 · Cited by 71
“A more recent study also suggested that brain volume loss in schizophrenia is associated with a genetic predisposition to produce more IL-1 β (Muller, 2018).”
Disruption of the blood–brain barrier in 22q11.2 deletion syndrome
Crockett, A. M., Ryan, S. K., Vásquez, A. H., Canning, C., Kanyuch, N., Kébir, H., Ceja, G., Gesualdi, J., Zackai, E. H., McDonald‐McGinn, D. M., et al. (2021) · Brain · doi:10.1093/brain/awab055 · Cited by 67
Association of Mitochondrial Biogenesis With Variable Penetrance of Schizophrenia
Li, J., Tran, O., Crowley, T. B., Moore, T. M., Zackai, E. H., Emanuel, B. S., McDonald‐McGinn, D. M., Gur, R. E., Wallace, D. C., & Anderson, S. A. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0762 · Cited by 63
Gooden, T. E., Gardner, M., Wang, J., Chandan, J. S., Beane, A., Haniffa, R., Taylor, S., Greenfield, S., Manaseki‐Holland, S., Thomas, G. N., et al. (2022) · The Lancet HIV · doi:10.1016/s2352-3018(21)00319-2 · Cited by 72
Murru, E., Carta, G., Manca, C., Sogos, V., Pistis, M., Melis, M., & Banni, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.587140 · Cited by 70
“…a relationship between neuroimmune function and neurodevelopment disorders such as autism and schizophrenia (Martínez-Gras et al., 2011; Chase et al., 2015; Gottfried and Bambini-Junior, 2018; Müller, 2018) as well as mood disorders (Scheggi et al., 2016; Pfau et al., 2018; Tufano and Pinna, 2020).”
BackgroundSex Differences in Neurodevelopmental Disorders: A Key Role for the Immune System
Breach, M. R., & Lenz, K. M. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_308 · Cited by 62
Is cyclooxygenase‐1 involved in neuroinflammation?
Ghazanfari, N., van Waarde, A., Dierckx, R., Doorduin, J., & de Vries, E. F. J. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24934 · Cited by 71
“…and brain damage, but is also associated with various psychiatric and neurodegenerative disorders, such as schizophrenia (Monji et al., 2009; Müller, 2018; Müller et al., 2015; Na et al., 2014; Najjar & Pearlman, 2015), depression (Benedetti et al., 2020; Najjar et al., 2013; Nettis &…”
BackgroundThe role of the retinoids in schizophrenia: genomic and clinical perspectives
Reay, W. R., & Cairns, M. J. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0566-2 · Cited by 65
Pełka-Wysiecka, J., Kaczmarczyk, M., Bąba-Kubiś, A., Liśkiewicz, P., Wroński, M., Skonieczna-Żydecka, K., Marlicz, W., Misiak, B., Starzyńska, T., Kucharska-Mazur, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101605 · Cited by 59
Solberg, D. K., Refsum, H., Andreassen, O. A., & Bentsen, H. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.14 · Cited by 61
“Several lines of evidence suggest that the pathophysiology of schizophrenia involves immune and inflammatory pathways that may have important aetiological and therapeutic implications (Anderson &Maes, 2013; Muller et al., 2015; Muller, 2018).”
BackgroundInteraction between TNF-α and oxidative stress status in first-episode drug-naïve schizophrenia
Zhu, S., Zhao, L., Fan, Y., Lv, Q., Wu, K., Lang, X., Li, Z., Yi, Z., & Geng, D. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104595 · Cited by 64
Mental Disorders and Oral Diseases: Future Research Directions
Joury, E., Kisely, S. R., Watt, R. G., Ahmed, N., Morris, A. J., Fortune, F., & Bhui, K. S. (2022) · Journal of Dental Research · doi:10.1177/00220345221120510 · Cited by 66
“There is growing evidence of a contribution of the latter to neuroinflammation involved in depression and schizophrenia (Miller and Raison 2016; Müller 2018).”
BackgroundIs There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?
Tufano, M., & Pinna, G. (2020) · Molecules · doi:10.3390/molecules25051062 · Cited by 59
“Schizophrenia has been associated with increased inflammation, suggesting that the neuroinflammatory processes may play a role in the pathophysiology of this prevalent mental disorder [107].”
BackgroundTreating disorders across the lifespan by modulating cholinergic signaling with galantamine
Metz, C. N., & Pavlov, V. A. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15243 · Cited by 64
“Immune dysfunction, inflammation, and neuroinflammation in schizophrenia have been described for decades (Müller, 2018) and elevated levels of cytokines in blood and cerebrospinal fluid have been demonstrated in schizophrenia patients (Müller, 2018).”
BackgroundOshaghi, M., Kourosh‐Arami, M., & Roozbehkia, M. (2022) · Neurological Sciences · doi:10.1007/s10072-022-06413-0 · Cited by 62
Regulation of Reactive Oxygen Species-Mediated Damage in the Pathogenesis of Schizophrenia
Madireddy, S., & Madireddy, S. (2020) · Brain Sciences · doi:10.3390/brainsci10100742 · Cited by 61
Teasdale, S. B., Mörkl, S., & Mueller‐Stierlin, A. S. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100070 · Cited by 78
“inflict typical alterations of dopaminergic, serotonergic, noradrenergic and glutamatergic neurotransmission and cause concomitant neuroinflammation including microglial activation (Müller, 2018; Hafizi et al., 2018).”
BackgroundKetogenic diet for schizophrenia: clinical implication
Sarnyai, Z., Kraeuter, A.-K., & Palmer, C. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000535 · Cited by 58
Salivary microbiome profiling reveals a dysbiotic schizophrenia-associated microbiota
Qing, Y., Xu, L., Cui, G., Sun, L., Hu, X., Yang, X., Jiang, J., Zhang, J., Zhang, T., Wang, T., et al. (2021) · Schizophrenia · doi:10.1038/s41537-021-00180-1 · Cited by 55
Association of acute psychosocial stress with oxidative stress: Evidence from serum analysis
Kim, E., Zhao, Z., Rzasa, J. R., Glassman, M., Bentley, W. E., Chen, S., Kelly, D. L., & Payne, G. F. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102138 · Cited by 52
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
“With respect to attenuation of neuroinflammation associated with schizophrenia [60], and building on several lines of preclinical data demonstrating minocycline’s potential to target dysfunctional glutamatergic, inflammatory, and oxidative stress pathways [61], it has been speculated that in conditions of hyperactive…”
De Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49
Narcolepsy and psychosis: A systematic review
Hanin, C., Arnulf, I., Maranci, J., Lecendreux, M., Levinson, D. F., Cohen, D., & Laurent‐Levinson, C. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13300 · Cited by 56
Kulaga, S. S., & Miller, C. W. T. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.05.008 · Cited by 57
“…al., 2020a; Shi et al., 2020), including during pregnancy (Yin et al., 2020), and serves as a marker of maternal immune activation that has been implicated in the pathogenesis of schizophrenia in offspring (Aguilar-Valles et al., 2020; Martins-Filho et al., 2020; Müller, 2018; Smith et al., 2007).”
InfluentialRegulatory mechanism and therapeutic potentials of naringin against inflammatory disorders
Peng, Y., Qu, R., Xu, S., Bi, H., & Guo, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24619 · Cited by 57
“Inflammation is a protective response to environmental exposure, infection, tissue damage, and autoimmune induction, mainly manifested as redness, swelling, heat, pain, immune cell infiltration, and dysfunction [62].”
BackgroundDietary Fatty Acids and Microbiota-Brain Communication in Neuropsychiatric Diseases
Marrone, M. C., & Coccurello, R. (2019) · Biomolecules · doi:10.3390/biom10010012 · Cited by 45
“Not only butyrate administration can promote the recovery of BDNF expression and memory impairment [249], but its activity as HDAC inhibitor provides a mechanistic evidence for the ability to suppress several LPS-induced pro-inflammatory factors [250], which are recognized components of SCZ pathogenesis [251].”
BackgroundSquassina, A., Manchia, M., Pisanu, C., Ardau, R., Arzedi, C., Bocchetta, A., Caria, P., Cocco, C., Congiu, D., Cossu, E., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00844-z · Cited by 54
Transposable elements in brain health and disease
Ahmadi, A., De Toma, I., Vilor-Tejedor, N., Eftekhariyan Ghamsari, M. R., & Sadeghi, I. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101153 · Cited by 46
Advances in cerebral palsy biomarkers
Savasan, Z. A., Kim, S. K., Oh, K. J., & Graham, S. F. (2020) · Advances in clinical chemistry · doi:10.1016/bs.acc.2020.04.006 · Cited by 50
Homotopic functional connectivity disruptions in schizophrenia and their associated gene expression
Cai, M., Ji, Y., Zhao, Q., Xue, H., Sun, Z., Wang, H., Zhang, Y., Chen, Y., Zhao, Y., Zhang, Y., et al. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120551 · Cited by 51
“In conclusion, our findings deepen the knowledge of the pathophysiology and genetic architecture underlying homotopic FC alterations in schizophrenia.”
Vagus nerve stimulation and Neurotrophins: a biological psychiatric perspective
Rosso, P., Iannitelli, A., Pacitti, F., Quartini, A., Fico, E., Fiore, M., Greco, A., Ralli, M., & Tirassa, P. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.034 · Cited by 51
Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020
Teixeira, A. L., Krause, T. M., Ghosh, L., Shahani, L., Machado‐Vieira, R., Lane, S. D., Boerwinkle, E., & Soares, J. C. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.34969 · Cited by 49
New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment
Faris, P. S., Pischedda, D., Palesi, F., & D'Angelo, E. U. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1386583 · Cited by 52
“Studies evidenced the involvement of neuro-inflammation (Müller, 2018) and autoinflammation in SZ (Delunardo et al., 2016) but microglia activation has not been confirmed by PET studies in humans (Marques et al., 2019).”
BackgroundChemokine alterations in the postmortem brains of suicide completers
Shinko, Y., Otsuka, I., Okazaki, S., Horai, T., Boku, S., Takahashi, M., Ueno, Y., Sora, I., & Hishimoto, A. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.10.008 · Cited by 42
Changes in Default-Mode Network Associated With Childhood Trauma in Schizophrenia
Dauvermann, M. R., Mothersill, D., Rokita, K., King, S., Holleran, L., Kane, R., McKernan, D. P., Kelly, J. P., Morris, D. W., Corvin, A. P., et al. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab025 · Cited by 46
Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets
Ľupták, M., Michaličková, D., Fišar, Z., Kitzlerová, E., & Hroudová, J. (2021) · World Journal of Psychiatry · doi:10.5498/wjp.v11.i7.277 · Cited by 49
Xie, M., Li, Z., Li, X., Ai, L., Jin, M., Jia, N., Yang, Y., Li, W., Xue, F., Zhang, M., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.06.007 · Cited by 39
Messina, A., Concerto, C., Rodolico, A., Petralia, A., Caraci, F., & Signorelli, M. S. (2023) · Brain Sciences · doi:10.3390/brainsci13060957 · Cited by 44
Elevated zonulin, a measure of tight-junction permeability, may be implicated in schizophrenia
Barber, G., Sturgeon, C., Fasano, A., Cascella, N. G., Eaton, W. W., McMahon, R. P., & Kelly, D. L. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.07.006 · Cited by 39
Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia
Shnayder, N. A., Khasanova, A. K., Strelnik, A., Al-Zamil, M., Otmakhov, A., Незнанов, Н. Г., Shipulin, G. A., Петрова, М. М., Garganeeva, N. P., & Nasyrova, R. F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911324 · Cited by 44
Vallés, A. S., & Barrantes, F. J. (2023) · Cells · doi:10.3390/cells12162051 · Cited by 41
“Augmented levels of pro-inflammatory cytokines have been found in schizophrenic patients as well [179].”
Women who suffer from schizophrenia: Critical issues
Seeman, M. V. (2018) · World Journal of Psychiatry · doi:10.5498/wjp.v8.i5.125 · Cited by 40
Neuroinflammation and schizophrenia – is there a link?
Chaves, C., Dursun, S. M., Tusconi, M., & Hallak, J. E. C. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1356975 · Cited by 56
Longitudinal study of inflammatory markers and psychopathology in schizophrenia
Feng, T., McEvoy, J. P., & Miller, B. J. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.10.003 · Cited by 38
Hidese, S., Hattori, K., Sasayama, D., Tsumagari, T., Miyakawa, T., Matsumura, R., Yokota, Y., Ishida, I., Matsuo, J., Yoshida, S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.594394 · Cited by 38
“…Bauer and Teixeira, 2018), including schizophrenia (Horvath andMirnics, 2014; Na et al., 2014; Muller et al., 2015; Khandaker and Dantzer, 2016; Muller, 2018), bipolar disorder (BD) (Rosenblat and McIntyre, 2015; Walther et al., 2017), and major depressive disorder (MDD) (SpernerUnterweger et…”
BackgroundResultLing, Z., Cheng, Y., Liu, X., Yan, X., Wu, L., Shao, L., Gao, J., Lei, W., Song, Q., Zhao, N., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02682-1 · Cited by 36
A conceptualized model linking matrix metalloproteinase-9 to schizophrenia pathogenesis
Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2019.12.015 · Cited by 38
Smirnova, L. P., Yarnykh, V. L., Parshukova, D. A., Kornetova, E. G., Semke, A. V., Usova, A. V., Pishchelko, A. O., Khodanovich, M. Y., & Ivanova, S. А. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01475-8 · Cited by 38
Zhuo, C., Zhao, F., Tian, H., Chen, J., Li, Q., Yang, L. X., Ping, J., Li, R., Wang, L., Xu, Y. J., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01999-7 · Cited by 37
“The vulnerability-stress-inflammation model, which includes the contribution of stress to schizophrenia on the basis of genetic susceptibility, is rapidly evolving in the field of schizophrenia research, and focuses on disturbances of cytokines and other inflammatory mediators potentially caused by pathogen exposures…”
BackgroundKovács, M. Á., Tényi, T., Kugyelka, R., Prenek, L., Hau, L., Magyar, É. E., Herold, R., Balogh, P., & Simon, D. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00996 · Cited by 34
Anti-Inflammatory Diets and Schizophrenia
Yun, H. S., & Yang, S. J. (2020) · Clinical Nutrition Research · doi:10.7762/cnr.2020.9.4.241 · Cited by 36
“In addition, chronic inflammation due to dietary and environmental factors may affect the development of schizophrenia, and aggravate or alleviate symptoms of schizophrenia [15,16].”
BackgroundEpilepsy in patients with schizophrenia: Pathophysiology and basic treatments
Adachi, N., & Ito, M. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108520 · Cited by 37
Bejerot, S., Sigra, S., Henriksson, E. W., Eklund, D., Hylén, U., & Humble, M. B. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.12.003 · Cited by 37
Ermakov, E. A., Melamud, M. M., Boiko, A. S., Kamaeva, D. A., Ivanova, S. А., Nevinsky, G. A., & Buneva, V. N. (2023) · Brain Sciences · doi:10.3390/brainsci13050836 · Cited by 36
Cui, L., Wang, X.-Y., Fu, Y., Liu, X., Wei, Y., Zhao, S., Gu, Y.-W., Fan, J.-W., Wu, W.-J., Gong, H., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02963-y · Cited by 36
“The vulnerability-stress-inflammation model [7] proposes that genetic risks and early life exposures, such as stress or infection, may promote a chronic pro-inflammatory state and subsequently lead to neurotransmission disturbances and brain structural changes that are relevant for schizophrenia [7, 8].”
BackgroundAbnormal microglial reactivity in gray matter of the prefrontal cortex in schizophrenia
Uranova, N. A., Vikhreva, O. V., & Рахманова, В. И. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102752 · Cited by 34
Steen, N. E., Rahman, Z., Szabó, A., Hindley, G., Parker, N., Cheng, W., Lin, A., O’Connell, K. S., Sheikh, M. A., Shadrin, A. A., et al. (2023) · Schizophrenia Bulletin · doi:10.1093/schbul/sbad082 · Cited by 35
“4 Studies of maternal gestational infections have identified a range of pathogens associated with SCZ, 5 suggesting neurodevelopmental effects of microbe triggered immune N. E. Steen et al activation 6,7 involving sustained changes of microglia.”
Chamera, K., Szuster-Głuszczak, M., Trojan, E., & Basta-Kaim, A. (2020) · Cells · doi:10.3390/cells9071676 · Cited by 31
“Because the data suggested that microglial cells might be intimately involved in the pathogenesis of schizophrenia [60,61], we explored potential alterations in the pro- (MhcII, Cd40, iNos, Il-1β, Tnf-α and Il-6) and anti-inflammatory (Arg1, Igf-1, Tgf-β and Il-4) factors that are also considered microglial markers (F…”
BackgroundCSA Study Group, Hoertel, N., Rotenberg, L., Blanco, C., de Raykeer, R. P., Hanon, C., Kaladjian, A., & Limosin, F. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01026-9 · Cited by 34
Ulivieri, M., Wierońska, J. M., Lionetto, L., Martinello, K., Cieślik, P., Chocyk, A., Curto, M., Menna, L. D., Iacovelli, L., Traficante, A., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa074 · Cited by 32
Dysregulation of phospholipase and cyclooxygenase expression is involved in Schizophrenia
Yang, X., Li, M., Jiang, J., Hu, X., Qing, Y., Sun, L., Yang, T., Wang, D., Cui, G., Gao, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103239 · Cited by 35
Metadata
- Authors
- Müller, N.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Müller, Norbert
- ORCID
- Müller, Norbert
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-10
- Volume
- 44
- Issue
- 5
- Pages
- 973-982
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6101562
- OpenAlex
- W2888647009
- Cited by
- 648
- References
- 130
- Citations by year
- 2026: 62 · 2025: 88 · 2024: 92 · 2023: 116 · 2022: 102 · 2021: 98 · 2020: 62 · 2019: 18 · 2018: 9
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- schizophrenia, neuroinflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Inflammation, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.